New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 6, 2014
14:32 EDTHSPHospira issues statement on paclitaxel supply and pricing
The company said, "Given recent misinformation, we at Hospira Canada feel it is very important to clarify and provide further context regarding the Canadian supply and pricing of paclitaxel a life-saving cancer medication. Most importantly, through Hospira's efforts, and working closely with Health Canada, a severe oncology treatment crisis was avoided, resulting in no patient disruption of a key oncolytic therapy. Contrary to media reports, Hospira did not increase our price for paclitaxel. In fact, Hospira offered a 75 percent discount off our list price of paclitaxel to Canadian purchasing groups that previously purchased the drug from another supplier that is not currently able to supply the market. The price referenced in media coverage is the list price for paclitaxel. Because we recognize the importance of paclitaxel, we offered this deep discount well before the issue became public by directly engaging each affected purchasing group in May, along with a firm commitment to apply the discount retroactively. We're hoping to quickly finalize agreements with the key purchasing groups that supply Canadian hospitals so they can obtain the discounted price and not pay the list price. It is expensive and complicated to meet this large, unexpected and sudden increase in demand. As well as offering the 75 percent discount, we have taken the following actions to ensure a smooth supply: We have increased local inventory levels across our portfolio to meet spikes in demand when shortages arise; We have expedited delivery to Canada ahead of other markets, while balancing the needs of our global patient base; We have worked with customers across the country to allocate inventories from institutions that had higher levels of inventory to where needs were critically necessary; We have made corporate investments exceeding $1 billion in recent years to expand production to provide a reliable supply of medically necessary products and prevent drug shortages, as we have been able to do with paclitaxel in Canada. Hospira has built a strong record in Canada, specifically in Montreal, with roots that date back to 1927, employing nearly 200 skilled and highly-trained individuals. We are proud to build on this heritage by quickly mobilizing our operations to provide life-saving cancer treatments to all Canadian patients who require them."
News For HSP From The Last 14 Days
Check below for free stories on HSP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2014
17:12 EDTHSPOn The Fly: Closing Wrap
Subscribe for More Information
13:00 EDTHSPFollow-up: Hospira upgraded to Buy from Hold at Deutsche Bank
Subscribe for More Information
12:24 EDTHSPHospira upgraded to Buy from Hold at Deutsche Bank
Subscribe for More Information
09:28 EDTHSPHospira sees FY14 gross margin 39%-40%
Subscribe for More Information
07:35 EDTHSPHospira sees FY14 adjusted EPS $2.30-$2.50, consensus $2.22
Raises FY14 cash flow from operations to $275M-$375M from $200M-$300M; Backs FY14 CapEx $375M-$425M; Backs FY14 depreciation and amortization to range $225M-$275M.
07:34 EDTHSPHospira reports Q2 adjusted EPS 72c, consensus 57c
Subscribe for More Information
July 29, 2014
15:53 EDTHSPNotable companies reporting before tomorrow's open
Subscribe for More Information
07:19 EDTHSPCBI to hold a conference
Subscribe for More Information
July 28, 2014
12:42 EDTHSPHospira, Danone rise following report of deal talks
Subscribe for More Information
08:12 EDTHSPHospira to obtain financial benefits from possible Danone deal, says Wells Fargo
After multiple media sources reported that Hospira (HSP) is in talks to buy Danone's (DANOY) medical nutrition business in a potential tax inversion deal, Wells Fargo estimates that the deal could be 9%-12% accretive to Hospira's EPS in 2015-2017 if it's an all-stock deal and 20%-22% accretive if it's a 50%/50% cash and stock deal. The firm The firm estimates that Hospira's tax bill would be cut to 21% in 2015 and 19% afterwards, from its current forecast of 24%-26% during those years. The firm thinks the strategic rationale for the deal from Hospira's perspective, however, is less clear. It keeps a Market Perform rating on the stock.
July 27, 2014
15:12 EDTHSP Hospira in talks to acquire Danone medical nutrition business, FT says
French consumer company Danone (DANOY) has been in negotiations to sell its medical nutrition business to Hospira (HSP) in a deal said to value the unit at $5B, says the Financial Times. The deal would also allow for U.S. based Hospira to domicile its tax base in Europe in a tax strategy known as an inversion, added the Financial Times. In prior reports, Nestle (NSRGY) and Fresenius (FMS) have also been mentioned as suitors for the Danone unit. Reference Link
July 23, 2014
10:02 EDTHSPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTHSPDeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:08 EDTHSPHospira initiated with a Hold at Deutsche Bank
Target $53.
July 18, 2014
10:48 EDTHSPHigh option volume stocks
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use